KBC Securities - Hyloris Pharmaceuticals (HYL) Hyloris FIRST LOOK: US deal on tranexamic acid RTU with Avenacy

Report

KBC Securities

Jacob Mekhael ...

Thomas Vranken

Hyloris FIRST LOOK: US deal on tranexamic acid RTU with Avenacy

Hyloris announced an exclusive license and supply agreement with Avenacy for tranexamic acid RTU in the US. The deal is set up as a profit sharing agreement with commercialisation expected to start in 2025. We reiterate our € 5 TP and Hold rating.

27/12/2024 1 EN

Underlying

Hyloris Pharmaceuticals

See profile

BE0974363955 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Jacob Mekhael

Thomas Vranken

Other Reports on these Companies

KBC Securities

Hyloris FIRST LOOK: Collaboration with AFT to develop HY-094 for iron deficiency

Hyloris entered into a late-stage research and development program in collaboration with AFT to introduce an injectable iron deficiency therapy (HY-094) to the global market – development costs and net margin from sales and licensing will be distributed equally. This announcement brings a new later stage product to the company's pipeline, for which Hyloris expects phase 3 development to start in the near-term. Given the size of the market, we expect this will be a high volume product and Hyloris will need to find a commercialisation partner with a large footprint. We note that Hyloris previous...

March 31, 2025 March 31, 2025 1 EN

KBC Securities

Morning Notes : HYL BB

: HYL BB

March 31, 2025 March 31, 2025 1 EN

KBC Securities

Hyloris FIRST LOOK: FY24 results come with a detailed pipeline update

Hyloris reported FY24 results with YE24 cash of € 23.6m (YE23: € 30.4m). Revenue grew to € 8.5m (from € 2.1m), though we note this included one-off milestone payments ($ 2.1m as well as an additional undisclosed amount). We are encouraged by the planned 9 regulatory submissions by YE26, though point out that US filing fees range $ 2-4m. Additionally, Hyloris will require extra funding to commercialise the near-term cardiology products in the US and is exploring multiple options. As such, while we acknowledge the company's operational progress, we'll look to see how Hyloris' funding plans evolv...

March 21, 2025 March 21, 2025 1 EN

Morning Notes : AGFB BB, DSFIR NA, IMMO BB, NEXTA BB, PROX BB, EKOP BB

: AGFB BB, DSFIR NA, IMMO BB, NEXTA BB, PROX BB, EKOP BB

14h / 6m 14h / 6m 1 EN

Guy Sips ... (+12)

Guy Sips
Jacob Mekhael
Kristof Samoy
Livio Luyten
Lynn Hautekeete
Michiel Declercq
Sharad Kumar S.P
Thibault Leneeuw
Thomas Couvreur
Thomas Vranken
Wim Hoste
Wim Lewi

Dynamic Top Pick List Update April 2025: Removing Gimv – Adding Adyen

In this April 2025 update of the KBC Securities' Dynamic Top Pick List, we are removing Gimv and adding Adyen. Since adding Gimv to the Dynamic Top Pick List in mid-December 2024, Gimv's performance has remained flat. However, month-to-date, it has increased by nearly 7%, while the indices have all declined. Given the backdrop of a tariff war brewing, we think it's time to remove Gimv from the Dynamic Top Pick List as medium-sized businesses are more likely to feel the pinch of lower demand and higher price uncertainty. However, we note that Gimv has consistently compounded its portfolio whil...

14h / 43m 14h / 43m 1 EN

Kristof Samoy

Kristof Samoy

Ekopak Surprising press release triggers sell off

Following December's profit warning, Ekopak again astounded the markets yesterday by announcing an approximate €8m revenue restatement of its recently published FY24 numbers. We were surprised to learn that the restatement pertained to revenue recognition of engineering efforts linked to the Waterkracht project, which was not disclosed at the time of the FY24 release. Additionally, the company is investigating balance sheet strengthening measures, which will likely result in a dilutive capital increase. Ekopak also announced plans to strengthen its management team, with further communication t...

14h / 44m 14h / 44m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Hyloris FIRST LOOK: US deal on tranexamic acid RTU with Avenacy

We are a financial services provider for several types of professional clients, each with distinct needs.

Hyloris FIRST LOOK: Collaboration with AFT to develop HY-094 for iron deficiency

Morning Notes : HYL BB

Hyloris FIRST LOOK: FY24 results come with a detailed pipeline update

Morning Notes : AGFB BB, DSFIR NA, IMMO BB, NEXTA BB, PROX BB, EKOP BB

Dynamic Top Pick List Update April 2025: Removing Gimv – Adding Adyen

Ekopak Surprising press release triggers sell off

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe